ROQ Roquefort Therapeutics Plc

TIDMROQ

RNS Number : 0535J

Roquefort Investments PLC

18 August 2021

18 August 2021

roquefort investments PLC

("Roquefort Investments" or the "Company")

Placing & Total Voting Rights

Roquefort Investments, an investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, announces that it has completed a placing of 3,000,000 new ordinary shares ("New Shares") to certain strategic investors at a price of 5 pence per share raising a total amount of GBP150,000 before expenses (the "Placing"). As part of the Placing the Company has also issued 1,500,000 warrants to subscribe for new ordinary shares at a price of 10 pence per share, expiring on 22 March 2023.

Application will be made to the Financial Conduct Authority and the London Stock Exchange for the New Shares (which will rank pari passu with the existing ordinary shares) to be admitted to the standard segment of the Official List and to trading on the Main Market of the London Stock Exchange ("Admission"). The issue of the New Shares is conditional on Admission. It is expected that Admission of the New Shares will occur at 8.00 a.m. on 23 August 2021.

Following Admission, the total issued share capital of the Company will consist of 36,900,000 ordinary shares of one penny each. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Stephen West, Chairman of Roquefort Investments, commented:

"We are very encouraged that the Company has attracted interest from strategic investors as we work towards delivering on our strategy to acquire a business in the medical biotechnology sector. We see this investment as confirmation that investors are confident in our management team delivering a value accretive transaction in the near term."

Enquiries:

 
 Roquefort Investments plc 
                                       +44 (0)20 3290 
 Stephen West (Chairman)                         9339 
 Optiva Securities Limited (Broker) 
                                       +44 (0)20 3411 
 Christian Dennis                                1881 
 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

LEI: 254900P4SISIWOR9RH34

About Roquefort Investments

Roquefort Investments was formed as an investment company to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. It is envisaged that such acquisition or acquisitions will trigger a reverse takeover in accordance with the listing rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEEAFPPFEFFEFA

(END) Dow Jones Newswires

August 18, 2021 07:02 ET (11:02 GMT)

Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024